TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26073393

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Statin therapy (unspecified)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Handgrip strength and resting respiratory exchange ratio (RER)
Number of subjects: 47
Study: 24935203

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Microwave ablation
Number of subjects: 111

Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 111
Study: 22576673

Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy (atorvastatin 80 mg)
Number of subjects: 18889

Group type: COMPARATOR
Intervention: Conventional/low-dose lipid-lowering therapy (atorvastatin 10 mg or simvastatin 20-40 mg)
Number of subjects: 18889
Study: 20519962

Group type: EXPERIMENTAL
Intervention: hu12F6mu (2.5, 5, or 10 mg)
Number of subjects: 27
Study: 17613574

Group type: EXPERIMENTAL
Intervention: Facial neuromuscular re-education (three sessions per day for six days per week for two weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional therapeutic measures
Number of subjects: 59
Study: 16222308

Group type: EXPERIMENTAL
Intervention: Cancer patients with lower socio-economic status
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Deprivation
Number of subjects: 609
Study: 12151920

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125%
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lidocaine 0.5%
Number of subjects: 8
Study: 10435374

Group type: EXPERIMENTAL
Intervention: Rest thallium-201 myocardial SPECT and exercise Tc-99m tetrofosmin first pass and SPECT
Number of subjects: 47
Study: 7482625

Group type: EXPERIMENTAL
Intervention: stanazolol
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 2301782

Group type: EXPERIMENTAL
Intervention: Inhaled triamcinolone, 200 micrograms four times daily (T)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo inhaler (P)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Inhaled triamcinolone (T) in higher compliers
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Inhaled triamcinolone (T) in lower compliers
Number of subjects: 37
Study: 6135874

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Prednisolone and azathioprine
Number of subjects: 43
Study: 29846713

Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 7658

Group type: COMPARATOR
Intervention: Coiling
Number of subjects: 7658
Study: 29115354

Group type: EXPERIMENTAL
Intervention: Daily blueberry juice intake (1× dosing)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Daily blueberry juice intake (⅓ doses taken thrice daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Washout period (7 days)
Number of subjects: 17
Study: 27592180

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with RehaCom cognitive training
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: RehaCom cognitive training
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual treatment (Control)
Number of subjects: 204
Study: 25107467

Group type: EXPERIMENTAL
Intervention: Myristic acid (14:0)
Number of subjects: 12403

Group type: EXPERIMENTAL
Intervention: Palmitic acid (16:0)
Number of subjects: 12403

Group type: EXPERIMENTAL
Intervention: Stearic acid (18:0)
Number of subjects: 12403

Group type: EXPERIMENTAL
Intervention: Pentadecanoic acid (15:0)
Number of subjects: 12403

Group type: EXPERIMENTAL
Intervention: Heptadecanoic acid (17:0)
Number of subjects: 12403

Group type: EXPERIMENTAL
Intervention: Arachidic acid (20:0)
Number of subjects: 12403

Group type: EXPERIMENTAL
Intervention: Behenic acid (22:0)
Number of subjects: 12403

Group type: EXPERIMENTAL
Intervention: Tricosanoic acid (23:0)
Number of subjects: 12403

Group type: EXPERIMENTAL
Intervention: Lignoceric acid (24:0)
Number of subjects: 12403
Study: 22284248

Group type: EXPERIMENTAL
Intervention: Sequential therapy (esomeprazole 40 mg BID, amoxicillin 1g BID for 1 week, followed by esomeprazole 40 mg BID, levofloxacin 500 mg QD, metronidazole 500 mg TID for 1 week)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard triple therapy (esomeprazole 40 mg BID, amoxicillin 1g BID, clarithromycin 500 mg BID for 2 weeks)
Number of subjects: 150
Study: 19148112

Group type: EXPERIMENTAL
Intervention: Massage therapy alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Massage therapy with kinesthetic stimulation (M/KS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 60
Study: 20426913

Group type: EXPERIMENTAL
Intervention: 99mTc-nanocolloid scintigraphy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Clinical remission criteria
Number of subjects: 40
Study: 16271642

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily
Number of subjects: 45852

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45852
Study: 12095065

Group type: EXPERIMENTAL
Intervention: tazarotene plus clindamycin phosphate lotion
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: tazarotene plus erythromycin/benzoyl peroxide
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: tazarotene plus clindamycin
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: tazarotene plus benzoyl peroxide
Number of subjects: 440
Study: 9590494

Group type: EXPERIMENTAL
Intervention: IMED Gemini PC‐2TX infusion pump
Number of subjects: 4

Group type: COMPARATOR
Intervention: Intravenous push method
Number of subjects: 4
Study: 8165649

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UF heparin), 10,000 IU s.c. b.d.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low molecular weight heparin (Fragmin), 5000 IU anti‐Factor Xa s.c. b.d.
Number of subjects: 80
Study: 17171954

Group type: EXPERIMENTAL
Intervention: 100% oxygen (F1O2 = 1.0)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 50% O2 (air‐O2 mixture, F1O2 = 0.5)
Number of subjects: 19
Study: 30591095

Group type: EXPERIMENTAL
Intervention: Acapella group (AG) - Oscillating positive expiratory pressure training
Number of subjects: 69
Study: 27116107

Group type: EXPERIMENTAL
Intervention: Intervention practices focusing on high value elements (HVEs) for quality improvement goals
Number of subjects: 1597

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 1597
Study: 24715102

Group type: EXPERIMENTAL
Intervention: Dual-Task-MOVING (DTM) group performed a dual-task during the MOVING phase
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dual-Task-AFTEREFFECT (DTAE) group performed a dual-task during the AFTER phase
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group performed no dual task
Number of subjects: 36
Study: 22175429

Group type: EXPERIMENTAL
Intervention: Internal teat sealant containing bismuth subnitrate
Number of subjects: 35

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Internal teat sealant
Number of subjects: 35
Study: 21046773

Group type: EXPERIMENTAL
Intervention: Tumescent infiltration solution at 25 degrees C (Group A)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Tumescent infiltration solution at 37 degrees C (Group B)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 15
Study: 18718770

Group type: EXPERIMENTAL
Intervention: Endoscopic GSV stripping
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional GSV stripping
Number of subjects: 60
Study: 15891319

Group type: EXPERIMENTAL
Intervention: DrotAA (24 microg.kg.hr for 96 hrs)
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1690
Study: 12633119

Group type: EXPERIMENTAL
Intervention: Oral olanzapine (N = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Depot antipsychotic control (N = 13)
Number of subjects: 26
Study: 10595865

Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylactic oral oseltamivir
Number of subjects: 0
Study: 9095688

Group type: EXPERIMENTAL
Intervention: One airflow filter on the expiratory limb
Number of subjects: 35

Group type: COMPARATOR
Intervention: Two airflow filters (one on the inspiratory limb and one on the expiratory limb)
Number of subjects: 35
Study: 1989427

Group type: EXPERIMENTAL
Intervention: 9 g fish oil/d (omega-3 fatty acid)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 9 g corn oil/d (omega-6 fatty acid)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: fish oil
Number of subjects: 46
Study: 6349914

Group type: EXPERIMENTAL
Intervention: Cefuroxime (1 g administered 30 minutes before operation and 3 and 10 hours after)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (physiological saline administered at the same times as cefuroxime)
Number of subjects: 100
Study: 31444115

Group type: EXPERIMENTAL
Intervention: Candle Burning (CB)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Toasting Bread (TB)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Frying Sausages (FS)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (Sham)
Number of subjects: 55
Study: 29702071

Group type: EXPERIMENTAL
Intervention: Incentive Spirometry (IS) in addition to routine physiotherapy (PHY/IS)
Number of subjects: 387
Study: 29117475

Group type: EXPERIMENTAL
Intervention: D-blade video
Number of subjects: 52

Group type: COMPARATOR
Intervention: Direct Macintosh laryngoscope
Number of subjects: 52
Study: 24468783

Group type: EXPERIMENTAL
Intervention: Daclatasvir (DCV) combined with pegylated interferon alpha-2b (PEG-IFN) and ribavirin (RBV)
Number of subjects: 8
Study: 22747768

Group type: EXPERIMENTAL
Intervention: epoprostenol 1 ng/kg/min
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: epoprostenol 2 ng/kg/min
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study: 20083483

Group type: EXPERIMENTAL
Intervention: Steerable sheath (group S)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-steerable sheath (group NS)
Number of subjects: 40
Study: 17045443

Group type: EXPERIMENTAL
Intervention: Semi-automated, 96-well format solid-phase extraction (SPE) method for alendronate determination
Number of subjects: 96

Group type: COMPARATOR
Intervention: Alendronate sodium tablets (70 mg)
Number of subjects: 96
Study: 16494040

Group type: EXPERIMENTAL
Intervention: Group A surgery
Number of subjects: 2792

Group type: EXPERIMENTAL
Intervention: Group B surgery
Number of subjects: 2792

Group type: EXPERIMENTAL
Intervention: Group C surgery
Number of subjects: 2792
Study: 11349937

Group type: EXPERIMENTAL
Intervention: Flaxseed (30 grams daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no placebo)
Number of subjects: 15
Study: 9589236

Group type: EXPERIMENTAL
Intervention: Gly‐‐>Arg substitution in codon 972 of the insulin receptor substrate‐1 gene in subjects with IGT
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Gly‐‐>Arg substitution in codon 972 of the insulin receptor substrate‐1 gene in subjects with NIDDM
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Normal control subjects aged > 50 years
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Subjects with IGT or NIDDM
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: NIDDM patients with the variant allele
Number of subjects: 1106
Study: 7744393

Group type: EXPERIMENTAL
Intervention: Interferon 1,000,000 u intramuscularly daily for 10 days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Vitamin C and inosine therapy intravenously daily for 10 days
Number of subjects: 57
Study: 2601863

Group type: EXPERIMENTAL
Intervention: L-sulpiride 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-sulpiride 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Droperidol 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 4595974

Group type: COMPARATOR
Intervention: Fluorouracil (FU) 15 mg/kg/day I.V. x 5 given monthly
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) 10 mg/kg/day I.V. on days 1 to 5; imidazole 4 carboxamide, 5 (3,3 dimethyl 1 triazeno) (ICDT) 3 mg/kg/day I.V. on days 1 and 2; vincristine (VCR) 0.025 mg/kg I.V. on day 1; bis (2 chloroethyl) 1 nitrosourea (BCNU) 1.5 mg/kg I.V. on day 1
Number of subjects: 52
Study: 30744600

Group type: COMPARATOR
Intervention: Hospital doctors
Number of subjects: 1749
Study: 28237263

Group type: EXPERIMENTAL
Intervention: Liraglutide 3·0 mg
Number of subjects: 2254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2254
Study: 26281344

Group type: EXPERIMENTAL
Intervention: Fetal health locus of control (FHLC) Scale - Internality Scale (FHLC‐I)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Fetal health locus of control (FHLC) Scale - Chances Scale (FHLC‐C)
Number of subjects: 256
Study: 23489216

Group type: EXPERIMENTAL
Intervention: Sumatriptan/naproxen sodium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21233387

Group type: EXPERIMENTAL
Intervention: Expressive writing assignment before the test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18835526

Group type: EXPERIMENTAL
Intervention: Ethyl pyruvate (EP) 7,500 mg administered intravenously starting after the induction of general anesthesia followed by 5 more doses of 7,500 mg every 6 hours.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 17907389

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) of Sanyinjiao (SP 6) at 2/100 Hz, 8-10 mA for 30 min, 3 times a week for 1 month (3 courses total)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) of Sanyinjiao (SP 6)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Medication group (nilestriol 2 mg, twice/month for 3 months; medrysone 2 mg, t.i.d. for 10 days from the 3rd month)
Number of subjects: 175
Study: 15841580

Group type: EXPERIMENTAL
Intervention: Titanium frameworks (test group)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Gold alloy castings (control group)
Number of subjects: 126
Study: 11566440

Group type: EXPERIMENTAL
Intervention: Alcohol intake (0.8 g/kg per day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9193324

Group type: EXPERIMENTAL
Intervention: FAC and DZR (after 300 mg/m2 doxorubicin)
Number of subjects: 201

Group type: COMPARATOR
Intervention: FAC and PLA (before amendment)
Number of subjects: 201
Study: 8253942

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 600 mg mifepristone
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Number of subjects: 220
Study: 4020747

Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group cognitive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group (treatment as usual)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual vs Group cognitive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up at 12 months
Number of subjects: 0
Study: 30954675

Group type: EXPERIMENTAL
Intervention: Supportive social incentives
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Competitive social incentives
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Collaborative social incentives
Number of subjects: 602

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 602
Study: 29602631

Group type: EXPERIMENTAL
Intervention: TAKE-IT intervention (text message, e-mail, visual cue reminders, and coaching)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group (coaching without feedback on adherence data)
Number of subjects: 169
Study: 27634158

Group type: EXPERIMENTAL
Intervention: Neurodynamic treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Advice to remain active (Control)
Number of subjects: 60
Study: 23796045

Group type: EXPERIMENTAL
Intervention: Sildenafil (3 mg/kg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21598242

Group type: EXPERIMENTAL
Intervention: Combination weekly docetaxel and carboplatin (cDC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential docetaxel followed by carboplatin (sDC)
Number of subjects: 0
Study: 19470159

Group type: EXPERIMENTAL
Intervention: Complete CapRI-scheme (cisplatin, Interferon alpha-2b, external beam radiation, and three cycles of 5-fluorouracil continuous infusion)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: De-escalated CapRI-scheme (omitting cisplatin)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Further de-escalated CapRI-scheme (omitting both cisplatin and external beam radiation)
Number of subjects: 135
Study: 17487762

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 6 months (less by 10% to their anaerobic threshold)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Drug treatment without training (Control)
Number of subjects: 185
Study: 15141270

Group type: EXPERIMENTAL
Intervention: Trainee group (n=133)
Number of subjects: 262

Group type: COMPARATOR
Intervention: No trainee group (n=129)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Between group differences
Number of subjects: 262
Study: 12972969

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 34
Study: 10228253

Group type: EXPERIMENTAL
Intervention: Sedation with intravenous midazolam
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sedation with intravenous saline (placebo group)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No intravenous cannula (control group)
Number of subjects: 180
Study: 8746143

Group type: EXPERIMENTAL
Intervention: Glass polyalkenoate cement
Number of subjects: 228

Group type: COMPARATOR
Intervention: Bis glycidyl methacrylate resin
Number of subjects: 228
Study: 1829368

Group type: EXPERIMENTAL
Intervention: Bendrofluazide (5 mg once daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6348314

Group type: EXPERIMENTAL
Intervention: diazepam, 15 to 40 mg/day
Number of subjects: 180

Group type: COMPARATOR
Intervention: sedative-benzodiazepines (less than eight months)
Number of subjects: 180

Group type: COMPARATOR
Intervention: sedative-benzodiazepines (eight months or more)
Number of subjects: 180
Study: 3952641

Group type: EXPERIMENTAL
Intervention: Low-dose-rate irradiation (Ra226)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: High-dose-rate irradiation (Ir192)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: High-dose-rate irradiation (Ir192) combined with percutaneous Co60 therapy
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Modified high-dose-rate irradiation (Ir192) scheme (reduction of dose from 10 to 7 Gy)
Number of subjects: 299
Study: 30390879

Group type: EXPERIMENTAL
Intervention: High Intensity Intermittent Training (HIIT) - 5 km running at 100% speed for 1 min interspersed with 1 min passive recovery, 3 times a week for 5 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Steady-State Training (SST) - 5 km running at 70% of vV̇O2peak continuously, 3 times a week for 5 weeks
Number of subjects: 20
Study: 29383331

Group type: EXPERIMENTAL
Intervention: Liberal oxygenation (recommended care)
Number of subjects: 4200

Group type: COMPARATOR
Intervention: Strategy that permits hypoxia to SpO2 >= 80% (permissive hypoxia)
Number of subjects: 4200

Group type: EXPERIMENTAL
Intervention: High flow using AirVO2 TM
Number of subjects: 4200

Group type: COMPARATOR
Intervention: Low flow delivery (routine care)
Number of subjects: 4200
Study: 25912786

Group type: EXPERIMENTAL
Intervention: Nutrition therapy (intensive, biometric parameter-oriented dietary counseling)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (regular dietary counseling)
Number of subjects: 20
Study: 23682433

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg daily for 2 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 20648930

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Iron sucrose (ISC)
Number of subjects: 3000
Study: 18580415

Group type: EXPERIMENTAL
Intervention: Near-maximal-intensity (95% VO2R)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity (75% VO2R)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Moderate-intensity (50% VO2R)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 61
Study: 16545120

Group type: EXPERIMENTAL
Intervention: 3 months of exercise therapy supervised by a physical therapist
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual care (information and advice about the complaints only)
Number of subjects: 136
Study: 14604454

Group type: EXPERIMENTAL
Intervention: Risperidone (0.5-3.0 mg/d) for 8 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10972850

Group type: EXPERIMENTAL
Intervention: SPf66
Number of subjects: 1207

Group type: COMPARATOR
Intervention: EPI vaccines
Number of subjects: 1207
Study: 8625432

Group type: EXPERIMENTAL
Intervention: MVC with MORA in supported rest position
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: MORA
Number of subjects: 7

Group type: COMPARATOR
Intervention: Rest position
Number of subjects: 7

Group type: COMPARATOR
Intervention: MVC with placebo
Number of subjects: 7

Group type: COMPARATOR
Intervention: MVC in intercuspal position
Number of subjects: 7
Study: 1728444

Group type: EXPERIMENTAL
Intervention: t-PA (0.49 MU/kg for 1 hour followed by 0.07 MU/kg per hour for 9 hours)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: t-PA
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 6329121

Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cholecystokinin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8